FDA
approval
· 2022-10-14
FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)
Summary
FDA approved a supplemental application for BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) from Gilead Sciences, Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)